Biological characteristics of micrometastatic cancer cells in bone marrow

被引:32
作者
Braun, S
Pantel, K
机构
[1] Univ Hamburg, Frauenklin, Klinikum Eppendorf, D-20246 Hamburg, Germany
[2] Univ Munich, Frauenklin, Munich, Germany
关键词
epithelial cancer; bone marrow; micrometastasis; cytokeratin; p53; erb-B2; MAGE antigens; integrins; CD44; EpCAM;
D O I
10.1023/A:1006212403983
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
There is emerging evidence that epithelial tumor cells are able to disseminate to secondary organs at an early stage of primary tumor development. One of the most prominent secondary organs screened for this type of dissemination is bone marrow. Even in cancer entities where overt skeletal metastases are rare (e.g., colorectal and ovarian cancer), bone marrow is a prognostically relevant indicator organ for the presence of hematogenous micrometastases. The currently available data suggest that bone marrow micrometastases represent a selected population of dormant cancer cells which still express a considerable degree of heterogeneity. The analysis of micrometastatic cells will open a new avenue to assess the molecular determinants of early tumor cell dissemination and subsequent outgrowth into overt metastases. Moreover, monitoring the elimination of bone marrow micrometastases and identification of treatment-resistant tumor cell clones may help to increase the efficacy of adjuvant therapy. This review summarizes the current knowledge on the biological characteristics of micrometastatic cancer cells in bone marrow of patients with solid epithelial malignancies.
引用
收藏
页码:75 / 90
页数:16
相关论文
共 134 条
  • [1] ALBELDA SM, 1993, LAB INVEST, V68, P4
  • [2] ALLAVICINI MG, 1995, P AM ASSOC CANC RES, V36, P69
  • [3] Allgayer H, 1997, CANCER RES, V57, P1394
  • [4] Ardini E, 1997, J BIOL CHEM, V272, P2342
  • [5] BACUS SS, 1993, CANCER RES, V53, P5251
  • [6] Phase II study of weekly intravenous recombinant humanized Anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast
    Baselga, J
    Tripathy, D
    Mendelsohn, J
    Baughman, S
    Benz, CC
    Dantis, L
    Sklarin, NT
    Seidman, AD
    Hudis, CA
    Moore, J
    Rosen, PP
    Twaddell, T
    Henderson, IC
    Norton, L
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) : 737 - 744
  • [7] Behrens J, 1992, Semin Cell Biol, V3, P169
  • [8] BERGER MS, 1988, CANCER RES, V48, P1238
  • [9] PROGNOSTIC-SIGNIFICANCE OF C-ERBB-2 EXPRESSION IN NODE NEGATIVE BREAST-CANCER
    BIANCHI, S
    PAGLIERANI, M
    ZAMPI, G
    CARDONA, G
    CATALIOTTI, L
    BONARDI, R
    CIATTO, S
    [J]. BRITISH JOURNAL OF CANCER, 1993, 67 (03) : 625 - 629
  • [10] Birchmeier C, 1996, ACTA ANAT, V156, P217